Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025

Rhea-AI Summary

Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced it will report its fourth quarter 2024 financial results after U.S. market close on Thursday, February 27, 2025. The company will host a conference call and webcast, which will be available on the 'Investors' section of Xenon's website with a replay option following the event.

The company is advancing an ion channel product portfolio focused on epilepsy and depression. Their lead candidate, azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications.

News Market Reaction – XENE

+0.89%

+0.89% Session move

In the trading session that priced this news, XENE gained 0.89%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its fourth quarter 2024 financial results after the close of U.S. financial markets on Thursday, February 27, 2025.

Conference Call/Webcast Information:

Date:	Thursday, February 27, 2025
Time:	4:30 pm Eastern Time (1:30 pm Pacific Time)
Webcast:	Pre-register here
Dial-In:	(800) 715-9871 toll-free or (646) 307-1963 for international callers
Conference ID:	8120798

A live webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com

FAQ

When will Xenon Pharmaceuticals (XENE) release Q4 2024 earnings?

Xenon Pharmaceuticals will release its Q4 2024 earnings after U.S. market close on Thursday, February 27, 2025.

What is Xenon's (XENE) lead drug candidate in development?

Azetukalner, a novel Kv7 potassium channel opener, is Xenon's most advanced drug candidate in late-stage clinical development for multiple indications.

What therapeutic areas does XENE focus on?

Xenon Pharmaceuticals focuses on neuroscience, specifically developing treatments for epilepsy and depression through their ion channel product portfolio.

Where can investors access XENE's Q4 2024 earnings webcast?

The earnings webcast will be available on the 'Investors' section of Xenon's website, with a replay option available after the event.